drugset
Drugs / trivalent inactivated influenza vaccine (TIV)
last change 2 days ago re-read 3 minutes ago

trivalent inactivated influenza vaccine (TIV)

also known as TIV

Vaccine

Developed for
influenza
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Stanford University · Washington University School of Medicine

Trials 2

today NCT07493460 · Ph 4 NCT01827462 · Ph 4
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT07493460 Aug 2025 → Oct 2026 expected immunodeficiency disease Washington University School of Medicine Active not recruiting No outcome recorded
Phase 4 NCT01827462 Oct 2007 → Dec 2015 influenza Stanford University Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as trivalent inactivated influenza vaccine (TIV) ClinicalTrials.gov intervention name — accepted as the source's own label NCT07493460 ↗
1

NCT01827462 ↗
Known as TIV “trivalent inactivated influenza vaccine (TIV)” NCT07493460 ↗
Modality Vaccine “Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.” NCT01827462 ↗
Route Intramuscular “four licensed vaccines administered intramuscularly at a single visit” NCT07493460 ↗